Lumos Pharma (NASDAQ:LUMO) Receives “Neutral” Rating from HC Wainwright

Lumos Pharma (NASDAQ:LUMO)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $4.25 price target on the stock. HC Wainwright’s target price points to a potential downside of 2.50% from the company’s previous close.

LUMO has been the subject of a number of other research reports. Oppenheimer cut their target price on shares of Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. EF Hutton Acquisition Co. I upgraded shares of Lumos Pharma to a “strong-buy” rating in a research report on Tuesday, September 24th.

Lumos Pharma Stock Performance

LUMO stock traded up $0.03 during trading on Friday, reaching $4.36. 52,866 shares of the company were exchanged, compared to its average volume of 104,348. The company has a market cap of $35.40 million, a P/E ratio of -0.98 and a beta of 0.76. The stock’s 50 day moving average price is $3.96 and its 200 day moving average price is $2.96. Lumos Pharma has a 52-week low of $1.37 and a 52-week high of $4.58.

Hedge Funds Weigh In On Lumos Pharma

An institutional investor recently raised its position in Lumos Pharma stock. Private Advisor Group LLC increased its position in Lumos Pharma, Inc. (NASDAQ:LUMO) by 2,380.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 744,513 shares of the company’s stock after buying an additional 714,500 shares during the period. Private Advisor Group LLC owned about 9.17% of Lumos Pharma worth $2,881,000 as of its most recent SEC filing. 33.99% of the stock is currently owned by hedge funds and other institutional investors.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.